Literature DB >> 9112447

Craniopharyngioma: improving outcome by early recognition and treatment of acute complications.

B Rajan1, S Ashley, D G Thomas, H Marsh, J Britton, M Brada.   

Abstract

PURPOSE: To assess the frequency, mode of presentation, treatment, and outcome of acute complications in patients with craniopharyngioma around the time of radiotherapy. METHODS AND MATERIALS: A review was made of 188 patients with craniopharyngioma treated with conservative surgery and external beam radiotherapy at the Royal Marsden Hospital between 1950 and 1992.
RESULTS: Twenty six (14%) (95% confidence interval: 9-19%) patients with craniopharyngioma developed acute deterioration immediately before, during and 2 months after radiotherapy with visual deterioration (19 patients), hydrocephalus (7 patients), and global deficit (7 patients). Cystic enlargement with or without hydrocephalus was the most common cause of deterioration. No patient or disease characteristics were predictive of deterioration on univariate or multivariate analysis. Eighteen patients had surgical intervention at the time of deterioration and survived the immediate period. Six of seven patients who did not have surgical intervention died. All patients who survived the postcomplication period completed the full course of external beam radiotherapy. The 10-year progression-free survival of 162 patients without deterioration was 86%, and of 18 patients with acute deterioration who recovered after surgery, 77%.
CONCLUSION: Patients with craniopharyngioma develop acute deterioration around the time of radiotherapy owing to cystic enlargement and/or hydrocephalus which does not represent tumor progression. Early recognition and appropriate surgical treatment followed by conventional full-dose radiotherapy are associated with good long-term outcome.

Entities:  

Mesh:

Year:  1997        PMID: 9112447     DOI: 10.1016/s0360-3016(96)00537-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Rapid recurrence of craniopharyngioma following recombinant human growth hormone replacement.

Authors:  Takafumi Taguchi; Toshihiro Takao; Yasumasa Iwasaki; Kyonghon Pooh; Mizuho Okazaki; Kozo Hashimoto; Yoshio Terada
Journal:  J Neurooncol       Date:  2010-03-28       Impact factor: 4.130

Review 2.  Surgical management of craniopharyngiomas.

Authors:  Ricardo J Komotar; Marie Roguski; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 3.  Radiotherapy of other sellar lesions.

Authors:  N Karavitaki
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 4.  Management of craniopharyngiomas.

Authors:  N Karavitaki
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

5.  Craniopharyngiomas in children: surgical experience at Children's Memorial Hospital.

Authors:  Tadanori Tomita; Robin M Bowman
Journal:  Childs Nerv Syst       Date:  2005-07-26       Impact factor: 1.475

6.  Craniopharyngioma.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2001-01       Impact factor: 3.598

Review 7.  Radiation therapy in the management of pediatric craniopharyngiomas--a review.

Authors:  John A Kalapurakal
Journal:  Childs Nerv Syst       Date:  2005-06-17       Impact factor: 1.475

Review 8.  Clinical controversies: proton therapy for pediatric tumors.

Authors:  Thomas E Merchant
Journal:  Semin Radiat Oncol       Date:  2013-04       Impact factor: 5.934

9.  Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children.

Authors:  Mohammad Maarouf; Faycal El Majdoub; Manuel Fuetsch; Mauritius Hoevels; Ralph Lehrke; Frank Berthold; Jürgen Voges; Volker Sturm
Journal:  Strahlenther Onkol       Date:  2015-11-05       Impact factor: 3.621

Review 10.  The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngioma.

Authors:  G Minniti; V Esposito; M Amichetti; R Maurizi Enrici
Journal:  Neurosurg Rev       Date:  2009-01-23       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.